Evaluation of human plasma protein binding of trabectedin (Yondelis™, ET-743)

Current Clinical Pharmacology

Volumn 4, Issue 1, 2009, Pages 38-42

  Beumer, Jan Handrick ^a,d   Lopez Lazaro, L ^b   Schellens, Jan H M ^a,c   Beijnen, Jos H ^a,c   Van Tellingen, Olaf ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b PHARMAMAR S A   (Spain)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Displacement; Human; Protein binding; Trabectedin

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; CEFTAZIDIME; CLOXACILLIN; DIAZEPAM; DICLOFENAC; DIGITOXIN; ERYTHROMYCIN; ONDANSETRON; PARACETAMOL; PHENYTOIN; PROPRANOLOL; TAMOXIFEN; TRABECTEDIN; VALPROIC ACID; WARFARIN; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; PLASMA PROTEIN; TETRAHYDROISOQUINOLINE DERIVATIVE;

BINDING SITE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ELIMINATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; REVIEW; ULTRAFILTRATION; ARTICLE; CHEMISTRY; DRUG INTERACTION; METABOLISM; PROTEIN BINDING;

ANTINEOPLASTIC AGENTS, ALKYLATING; BLOOD PROTEINS; DIOXOLES; DRUG INTERACTIONS; HUMANS; PHENYTOIN; PROTEIN BINDING; TETRAHYDROISOQUINOLINES; ULTRAFILTRATION;

EID: 65549101664     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488409787236047     Document Type: Review

References (21)

1. Committee for Medicinal Products for Human Use. (2008). Product Information 17/03/2008 Yondelis-H-C-773-IB-02. European Medicines Agency.
2. Carter NJ, Keam SJ. Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 2007; 67: 2257-76.
3. Moore BM, Seaman FC, Wheelhouse RT, Hurley LH. Mechanism for the catalytic activation of ecteinscidin 743 and its subsequent alkylation of guanine N2. J Am Chem Soc 1998; 120: 2490-1.
4. van Kesteren C, de Vooght MM, Lopez-Lazaro L et al. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin. Anticancer Drugs 2003; 14: 487-502.
5. Baker SD, Li J, ten Tije AJ et al. Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther 2005; 77: 43-53.
6. Wright JD, Boudinot FD, Ujhelyi MR. Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet 1996; 30: 445-62.
7. Paxton JW. Protein binding of methotrexate in sera from normal human beings: effect of drug concentration, pH, temperature, and storage. J Pharmacol Methods 1981; 5: 203-13.
8. Meyer FP. Indicative therapeutic and toxic drug concentrations in plasma: a tabulation. Int J Clin Pharmacol Ther 1994; 32: 71-81.
9. Goodman, Gilman. Goodman & Gilman's The pharmacological basis of therapeutics. 1996 New York, Chicago, San Francisco, Lisbon, London, Madrid, Mexico City, Milan, New Delhi, San Juan, Seoul, Singapore, Sydney, Toronto, McGraw-Hill.
10. Dowsett M, Cuzick J, Howell A, Jackson I. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. Br J Cancer 2001; 85: 317-24.
11. Beumer JH, Rademaker-Lakhai JM, Rosing H, Lopez-Lazaro L, Beijnen JH, Schellens JH. Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer. Invest New Drugs 2005; 23: 429-36.
12. Lee KJ, Mower R, Hollenbeck T et al. Modulation of nonspecific binding in ultrafiltration protein binding studies. Pharm Res 2003; 20: 1015-21.
13. Rosing H, Hillebrand MJ, Jimeno JM et al. Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Mass Spectrom 1998; 33: 1134-40.
14. Rowland M, Tozer TN. Clinical pharmacokinetics - concepts and applications. 1995 Baltimore, Philadelphia, Hong Kong, London, Munich, Sydney, Tokyo, Williams & Wilkins.
15. Kodama H, Kodama Y, Shinozawa S, Kanemaru R, Todaka K, Mitsuyama Y. Serum protein binding kinetics of phenytoin in monotherapy patients. J Clin Pharm Ther 1998; 23: 361-5.
16. Gomez Bellver MJ, Garcia Sanchez MJ, Alonso Gonzalez AC, Santos BD, Dominguez-Gil A. Plasma protein binding kinetics of valproic acid over a broad dosage range: therapeutic implications. J Clin Pharm Ther 1993; 18: 191-7.
17. Lesko LJ, Narang PK, Yeager L, Cutler NR. Salicylate protein binding in serum from young and elderly subjects as measured by diafiltration. Eur J Clin Pharmacol 1985; 28: 339-45.
18. Ojingwa JC, Spahn-Langguth H, Benet LZ. Reversible binding of tolmetin, zomepirac, and their glucuronide conjugates to human serum albumin and plasma. J Pharmacokinet Biopharm 1994; 22: 19-40.
19. Stryer L. Biochemistry. 1995 New York, W.H. Freeman and Company.
20. Chamouard JM, Barre J, Urien S, Houin G, Tillement JP. Diclofenac binding to albumin and lipoproteins in human serum. Biochem Pharmacol 1985; 34: 1695-700.
21. Hage DS, Sengupta A. Characterisation of the binding of digitoxin and acetyldigitoxin to human serum albumin by high-performance affinity chromatography. J Chromatogr B Biomed Sci Appl 1999; 724: 91-100.